Relationship between equol producer status and metabolic parameters in 743 Japanese women: Equol producer status is associated with antiatherosclerotic conditions in women around menopause and early postmenopause

Menopause

Volumn 24, Issue 2, 2017, Pages 216-224

  Yoshikata, Remi ^a,b   Myint, Khin Z ^b   Ohta, Hiroaki ^c  

^a Hamasite Clinic   (Japan)

^b Tokyo Midtown Medicine   (Japan)

^c Women's Medical Center of Sanno Medical Center   (Japan)

Author keywords

Equol; Equol producer; Menopause; Metabolic parameters

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ARACHIDONIC ACID; C REACTIVE PROTEIN; EQUOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; TRIACYLGLYCEROL; URIC ACID; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; HIGH DENSITY LIPOPROTEIN; PEPTIDE;

ADULT; AGE; AGED; ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; BODY FAT DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; INTRAPERITONEAL FAT; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MENOPAUSE; METABOLISM; MIDDLE AGED; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PULSE WAVE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VERY ELDERLY; ADIPOSE TISSUE; AGING; BIOSYNTHESIS; BLOOD; MULTIVARIATE ANALYSIS; PHYSIOLOGY; STATISTICAL MODEL; URINE; YOUNG ADULT;

ADIPOSE TISSUE; ADULT; AGED; AGED, 80 AND OVER; AGING; ARACHIDONIC ACID; C-REACTIVE PROTEIN; COLLAGEN TYPE I; CROSS-SECTIONAL STUDIES; EICOSAPENTAENOIC ACID; EQUOL; FEMALE; HUMANS; LIPOPROTEINS, HDL; LOGISTIC MODELS; MENOPAUSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDES; POSTMENOPAUSE; PULSE WAVE ANALYSIS; TRIGLYCERIDES; URIC ACID; YOUNG ADULT;

EID: 84988692859     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000743     Document Type: Article

References (73)

1. Watanabe S, Yamaguchi M, Sobue T, et al. Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J Nutr 1998;128:1710-1715
2. Bovee TF, Schoonen WG, Hamers AR, Bento MJ, Peijnenburg AA. Screening of synthetic and plant-derived compounds for (anti)estrogenic and (anti)androgenic activities. Anal Bioanal Chem 2008;390:1111-1119
3. Rufer CE, Kulling SE. Antioxidant activity of isoflavones and their major metabolites using different in vitro assays. J Agric Food Chem 2006;54:2926-2931
4. Hwang CS, Kwak HS, Lim HJ, et al. Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration. J Steroid Biochem Mol Biol 2006;101:246-253
5. Mueller SO, Simon S, Chae K, Metzler M, Korach KS. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor a (ERa) and ERß in human cells. Toxico Sci 2004;80:14-25
6. Muthyala RS, Ju YH, Sheng S, et al. Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R-and S-equol and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg Med Chem 2004;12: 1559-1567
7. Ishiwata N, Melby MK, Mizuno S, Watanabe S. New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. Menopause 2009;16:141-148
8. Aso T. Equol improves menopausal symptoms in Japanese women. J Nutr 2010;140:1386S-1389S
9. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-A clue to the effectiveness of soy and its isoflavones. J Nutr 2002;132:3577-3584
10. Liu ZM, Ho SC, Chen YM, Liu J, Woo J. Cardiovascular risks in relation to daidzein metabolizing phenotypes among Chinese postmenopausal women. PLoS One 2014;9:e87861
11. Ishimi Y. Dietary equol and bone metabolism in postmenopausal Japanese women and osteoporotic mice. J Nutr 2010;140:1373S-1376S
12. Weaver C, Legette L. Equol, via dietary sources or intestinal production, may ameliorate estrogen deficiency-induced bone loss. J Nutr 2010;140:1377S-1379S
13. Setchell KD, Clerici C, Lephart ED, et al. S-equol, a potent ligand for estrogen receptor ß, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 2005;81:1072-1079
14. Akaza H, Miyanaga N, Takashima N, et al. Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol 2004;34:86-89
15. van der Velpen V, Hollman PC, van Nielen M, et al. Large interindividual variation in isoflavone plasma concentration limits use of isoflavone intake data for risk assessment. Eur J Clin Nutr 2014;68:1141-1147
16. Franke AA, Lai JF, Halm BM, et al. Equol production changes over time in postmenopausal women. J Nutr Biochem 2012;23:573-579
17. Faughnan MS, Hawdon A, Ah-Singh E, Brown J, Millward DJ, Cassidy A. Urinary isoflavone kinetics: the effect of age, gender, food matrix and chemical composition. Br J Nutr 2004;91:567-574
18. Ko TF, Tsai HS, Lin SM, Liu CD, Learn SP, Chiou RYY. GC-MS determined distribution of urinary equol producers as affected by age, gender, and repeated ingestions of soymilk. J Food Sci 2010;75:H306-H310
19. Setchell KD, Brown NM, Summer S, King EC, Heubi JE, Cole S, Guy T, Hokin B. Dietary factors influence production of the soy isoflavone metabolite s-(-)equol in healthy adults. J Nutr 2013;143:1950-1958
20. Acharjee S, Zhou JR, Elajami TK, Welty FK. Effect of soy nuts and equol status on blood pressure, lipids and inflammation in postmenopausal women stratified by metabolic syndrome status. Metabolism 2015;64: 236-243
21. Rangel-Huerta OD, Pastor-Villaescusa B, Aguilera CM, Gil A. A systematic review of the efficacy of bioactive compounds in cardiovascular disease: phenolic compounds. Nutrients 2015;7:5177-5216
22. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998;68:1375S-1379S
23. Morabito N, Crisafulli A, Vergara C, et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res 2002;17:1904-1912
24. Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 2000;72:844-852
25. Chen YM, Ho SC, Lam SS, Ho SS, Woo JL. Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. J Clin Endocrinol Metab 2003;88:4740-4747
26. Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 2004;292:65-74
27. Lampe JW, Karr SC, Hutchins AM, Slavin JL. Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 1998;217:335-339
28. Rowland IR, Wiseman H, Sanders TAB, Adlercreutz H, Bowey EA. Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora nutrition and cancer. Nutr Cancer 2000;36:27-32
29. Houtkooper LB, Lohman TG, Going SB, Howell WH. Why bioelectrical impedance analysis should be used for estimating adiposity. Am J Clin Nutr 1996;64:436S-448S
30. Yoshizumi T, Nakamura T, Yamane M, et al. Abdominal fat: standardized technique for measurement at CT. Radiology 1999;211: 283-286
31. Shepherd JA, Cheng XG, Lu Y, et al. Universal standardization of forearm bone densitometry. J Bone Miner Res 2002;17:734-745
32. Morton MS, Arisaka O, Miyake N, Morgan LD, Evans BA. Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. J Nutr 2002;132:3168-3171
33. Mandar R, Mikelsaar M. Transmission of mother's microflora to the newborn at birth. Biol Neonate 1996;69:30-35
34. Toth MJ, Tchernof A, Sites CK, et al. Effect of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disord 2000;24:226-231
35. Suk Hwa Jung, Kyoung Hwa Ha, Dae Jung Kim. Visceral fat mass has stronger associations with diabetes and prediabetes than other anthropometric obesity indicators among Korean adults. Yonsei Med J 2016;57:674-680
36. Despres JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012;126:1301-1313
37. Preis SR, Massaro JM, Robins SJ, et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. Obesity (Silver Spring) 2010;18:2191-2198
38. Pou KM, Massaro JM, Hoffmann U, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007;116:1234-1241
39. van der Velpen V, Geelen A, Hollman PC, Schouten EG, van Veer P, Afman LA. Isoflavone supplement composition and equol producer status affect gene expression in adipose tissue: a double-blind, randomized, placebo-controlled crossover trial in postmenopausal women. Am J Clin Nutr 2014;100:1269-1277
40. Meyer BJ, Larkin TA, Owen AJ, et al. Limited lipid-lowering effects of regular consumption of whole soybean foods. Ann Nutr Metab 2004;48:67-78
41. Cai Y, Guo K, Chen C, et al. Soya isoflavone consumption in relation to carotid intima-media thickness in Chinese equol excretors aged 40-65 years. Br J Nutr 2012;108:1698-1704
42. Guo K, Zhang B, Chen C, et al. Daidzein metabolising phenotypes in relation to serum lipids and uric acid in adults in Guangzhou. China Br J Nutr 2010;104:118-124
43. Adamopoulos D, Vlassopoulos C, Seitanides B, Contoyiannis P, Vassilopoulos P. The relationship of sex steroids to uric acid levels in plasma and urine. Acta Endocrinol (Copenh) 1977;85:198-208
44. Nicholls A, Snaith ML, Scott JT. Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J 1973;1:449-451
45. Yahyaoui R, Esteva I, Haro-Mora JJ, Almaraz MC, et al. Effect of longterm administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons. Clin Endocrinol Metab 2008;93: 2230-2233
46. Takiue Y, Hosoyamada M, Kimura M, Saito H. The effect of female hormones upon urate transport systems in the mouse kidney. Nucleosides Nucleotides Nucleic Acids 2011;30:113-119
47. Khan N, Sultana S. Abrogation of potassium bromate-induced renal oxidative stress and subsequent cell proliferation response by soy isoflavones in Wistar rats. Toxicology 2004;201:173-184
48. Qin Y, Shu F, Zeng Y, et al. Daidzein supplementation decreases serum triglyceride and uric acid concentrations in hypercholesterolemic adults with the effect on triglycerides being greater in those with the GA compared with the GG genotype of ESR-b RsaI. J Nutr 2014;144:49-54
49. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006;145:21-29
50. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347: 1557-1565
51. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391-397
52. Chan YH, Lau KK, Yiu KH, et al. Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischemic stroke. Eur Heart J 2008;29:2800-2807
53. Dong J-Y, Wang P, He K, Qin L-Q. Effect of soy isoflavones on circulating C-reactive protein in postmenopausal women: meta-analysis of randomized controlled trials. Menopause 2011;18:1256-1262
54. Ninomiya T, Nagata M, Hata J, et al. Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: the Hisayama Study. Atherosclerosis 2013;231:261-267
55. Serikawa T, Miura S, Okabe M, et al. Ratio of eicosapentaenoic acid to arachidonic acid is a critical risk factor for acute coronary syndrome in middle-aged older patients as well as younger adult patients. J Cardiol 2014;63:35-40
56. Bolca S, Possemiers S, Herregat A, et al. Microbial and dietary factors are associated with the equol producer phenotype in healthy postmenopausal women. J Nutr 2007;137:2242-2246
57. Burdge GC, Wootton SA. Conversion of a-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br J Nutr 2002;88:411-420
58. Burdge GC, Calder PC. Conversion of a-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod Nutr Dev 2005;455: 581-597
59. Tormala RM, Appt S, Clarkson TB, Tikkanen MJ, et al. Individual differences in equol production capability modulate blood pressure in tibolone-treated postmenopausal women: lack of effect of soy supplementation. Climacteric 2007;10:471-479
60. Tormala R, Appt S, Clarkson TB, et al. Equol production capability is associated with favorable vascular function in postmenopausal women using tibolone; no effect with soy supplementation. Atherosclerosis 2008;198:174-178
61. Kreijkamp-Kaspers S, Kok L, Bots ML, et al. Randomized controlled trial of the effects of soy protein containing isoflavones on vascular function in postmenopausal women. Am J Clin Nutr 2005;81:189-195
62. Joy S, Siow RC, Rowlands DJ, et al. The isoflavone equol mediates rapid vascular relaxation Ca2 and thorn-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt phosphorylation in human endothelial cells. J Biol Chem 2006;281:27335-27345
63. Kang JS, Yoon YD, Han MH, et al. Equol inhibits nitric oxide production and inducible nitric oxide synthase gene expression through down-regulating the activation of Akt. Int Immunopharmacol 2007;7: 491-499
64. Khosla S, Riggs B. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol Metab Clin N Am 2005;34:1015-1030
65. Taku K, Melby MK, Kurzer MS, Mizuno S, Watanabe S, Ishimi Y. Effects of soy isoflavone supplements on bone turnover markers in menopausal women: systematic review and meta-analysis of randomized controlled trials. Bone 2010;47:413-423
66. Wu J, Oka J, Ezaki J, et al. Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial. Menopause 2007;14:866-874
67. Ohtomo T, Uehara M, Penalvo JL, et al. Comparative activities of daidzein metabolites, equol and O-desmethylangolensin, on bone mineral density and lipid metabolism in ovariectomized mice and in osteoclast cell cultures. Eur J Nutr 2008;47:273-279
68. Usui T, Tochiya M, Sasaki Y, et al. Effects of natural S-equol supplements on overweight or obesity and metabolic syndrome in the Japanese, based on sex and equol status. Clin Endocrinol 2013;78:365-372
69. Uchiyama S, Tomomi U, Kyosuke M, Seiichi S, Takeshi A, Tomoko S. The cross-sectional study of the relationship between soy isoflavones, equol and the menopausal symptoms in Japanese women. J Jpn Menopause Soc 2007;15:28-37
70. Newton KM, Reed SD, Uchiyama S, et al. A cross-sectional study of equol producer status and self-reported vasomotor symptoms. Menopause 2015;22:489-495
71. Jenks BH, Iwashita S, Nakagawa Y, et al. A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency. J Womens Health 2012;21:674-682
72. Hazim S, Curtis PJ, Schar MY, Ostertag LM, Kay CD, Minihane AM, Cassidy A. Acute benefits of the microbial-derived isoflavone metabolite equol on arterial stiffness in men prospectively recruited according to equol producer phenotype: a double-blind randomized controlled trial. Am J Clin Nutr 2016;103:694-702
73. Yoshikata R, Ohta H, Myint K. Comparison of equol containing dietary supplement with hormone replacement therapy in the Improvement of vasomotor symptoms and secondary vascular Actions in women with climacteric symptoms. Poster presented at the annual meeting of The North American Menopause Society 2015, Las Vegas, NV. Menopause 2015;22:1384. Abstract P-33